Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Related LGND
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Fed Says Districts Were Optimistic On Economic Outlook; Yahoo! Falls On Downbeat Results
Related GSK
Markets Little Changed Ahead Of The Federal Reserve's Policy Decision
Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine CR Yo Apotex; Apotex Can No Longer Supply Authorized Generic Product
Bayer Buys Merck Consumer Care Unit (Fox Business)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA


Most Popular

Related Articles (LGND + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters